PharmaResearch Co., Ltd. (KOSDAQ: 214450)

PharmaResearch Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	131,078	67,245	72,931	41,674	26,715	19,738
Short-Term Investments	35,193	56,549	67,989	2,000	8,981	3,000
Trading Asset Securities	50,141	36,505	43,423	113,123	43,571	46,292
Cash & Short-Term Investments	216,412	160,298	184,343	156,798	79,267	69,029
Cash Growth	5.50%	-13.04%	17.57%	97.81%	14.83%	-8.44%
Accounts Receivable	34,314	31,400	32,304	27,741	22,827	20,197
Other Receivables	5,097	3,301	2,757	975.32	873.4	375.03
Receivables	51,747	35,998	36,234	30,490	26,343	20,572
Inventory	53,033	50,232	24,453	17,342	20,781	13,928
Prepaid Expenses	-	1,191	667.94	701.54	373.73	97.21
Other Current Assets	16,482	8,746	1,647	1,460	639.42	846.03
Total Current Assets	337,674	256,465	247,345	206,792	127,404	104,473
Property, Plant & Equipment	146,088	123,061	117,960	109,481	94,046	73,886
Long-Term Investments	93,557	96,951	40,718	44,911	42,511	39,356
Goodwill	13,042	11,652	13,810	16,764	12,492	13,738
Other Intangible Assets	18,507	18,709	22,720	24,825	26,233	29,806
Long-Term Deferred Tax Assets	8,309	4,476	8,667	3,166	3,162	2,292
Long-Term Deferred Charges	1,302	1,614	1,297	1,200	578.13	-
Other Long-Term Assets	19,323	18,415	21,105	15,715	13,407	2,752
Total Assets	640,818	535,281	478,055	427,647	319,831	269,925
Accounts Payable	8,194	2,831	3,527	2,939	1,876	5,359
Accrued Expenses	1,485	974.34	860.08	702.95	533.87	492.04
Short-Term Debt	21,314	32,345	18,867	18,873	17,854	1,236
Current Portion of Long-Term Debt	20	33.3	87.4	726.52	610	1,913
Current Portion of Leases	1,707	628.25	1,620	1,161	1,117	358.34
Current Income Taxes Payable	16,252	11,357	10,136	6,851	6,222	3,584
Current Unearned Revenue	-	27.69	11.36	-	-	-
Other Current Liabilities	34,390	17,703	19,144	16,751	7,637	5,648
Total Current Liabilities	83,362	65,899	54,253	48,005	35,849	18,590
Long-Term Debt	7,138	970.72	45,359	43,385	10,505	16,496
Long-Term Leases	1,725	329.91	835.48	1,466	2,324	939.83
Long-Term Deferred Tax Liabilities	2,301	2,794	3,741	4,514	4,746	5,404
Other Long-Term Liabilities	1,604	1,911	1,648	1,175	1,133	72.86
Total Liabilities	97,785	73,087	106,399	99,288	55,420	41,502
Common Stock	5,232	5,160	5,056	5,056	4,895	4,777
Additional Paid-In Capital	187,789	175,428	157,582	152,413	133,405	126,652
Retained Earnings	324,447	260,787	190,862	154,018	112,615	82,783
Treasury Stock	-4,638	-4,638	-5,260	-5,260	-5,260	-5,260
Comprehensive Income & Other	-2,804	-3,633	-4,737	-785.15	-232.35	121.9
Total Common Equity	510,026	433,104	343,503	305,442	245,423	209,075
Minority Interest	32,185	29,091	28,153	22,917	18,989	19,349
Shareholders' Equity	543,033	462,195	371,656	328,359	264,411	228,424
Total Liabilities & Equity	640,818	535,281	478,055	427,647	319,831	269,925
Total Debt	31,904	34,307	66,768	65,611	32,410	20,943
Net Cash (Debt)	184,507	125,991	117,575	91,187	46,857	48,087
Net Cash Growth	19.09%	7.16%	28.94%	94.61%	-2.56%	-12.67%
Net Cash Per Share	17472.15	11931.85	11785.88	9070.92	4928.76	5095.13
Filing Date Shares Outstanding	10.34	10.2	9.98	9.98	9.65	9.42
Total Common Shares Outstanding	10.34	10.2	9.98	9.98	9.65	9.42
Working Capital	254,312	190,566	193,092	158,787	91,555	85,883
Book Value Per Share	49305.53	42459.18	34433.24	30617.96	25424.37	22197.68
Tangible Book Value	478,477	402,743	306,974	263,854	206,698	165,531
Tangible Book Value Per Share	46255.62	39482.74	30771.48	26449.11	21412.71	17574.63
Land	18,617	18,617	18,617	14,064	14,064	7,081
Buildings	81,780	81,472	80,151	52,235	52,135	45,537
Machinery	48,774	41,375	30,766	27,162	22,544	21,806
Construction In Progress	32,690	12,459	12,200	32,985	16,386	9,515

Source: S&P Capital IQ. Standard template. Financial Sources.